An analysis of previously published CD34 and FAK (PTK2) mRNA levels in AML cell lines and two AML patient cohorts showed a subtle but consistent correlation between FAK and CD34 [32,36,37], suggesting that defactinib might be most effective in more primitive CD34high AML cells. The gene discussed is CD34; the disease is acute myeloid leukemia.